EN DE
Watch Anterogen.Co.Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Anterogen.Co.Ltd (065660) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Anterogen.Co.Ltd stock KRW 4,741, price KRW 13,140, that is 63.9% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7065660003

AC Anterogen.Co.Ltd logo Thin data Nov 4, 2026

Anterogen.Co.Ltd

065660 · KQ
Very expensive, weak quality

Our calculation puts a fair price 64% below what the stock costs today.

Low debt
Quality 42/100
Expensive Growth (revenue 5y +12.7 %/yr in KRW)
Revenue last quarter 14% below a year ago.
Fair value 4,741 KRW · Strongly overvalued
Loss-making · -85.6% net margin (TTM)
Negative free cash flow
Trails peers (0/10)
Narrow moat 13/100
Thin data
Watch Anterogen.Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

97,700 KRW 12,600 KRW Fair Value 4,741 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 12,600 KRW – 97,700 KRW · fair‑value band 3,129 KRW – 5,926 KRW · the 13,140 KRW price screens above the 4,741 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Anterogen.Co.Ltd in your weekly email

Every Wednesday you see whether Anterogen.Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Anterogen. Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally.

Show moreShow less

The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension.

It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material.

In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.

Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Stock analysis

Anterogen.Co.Ltd (065660) currently trades at 13,140 KRW, while our model-based Fair Value estimate is 4,741 KRW, 64% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 3,129 KRW (bear) to 5,926 KRW (bull), the price of 13,140 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Anterogen.Co.Ltd reported revenue of 7.5B KRW in FY2025 versus 8.1B KRW in FY2021, a compound −1.9%/yr. Reported net income was −1.4B KRW in FY2025.

Key figures

Market cap 131B KRW (≈ $97.2M) Micro · P/S ratio 18.4 · Net margin −85.6% · Return on equity −232% · Return on assets (EBIT) −3.1% (5-year average) · Operating margin −54.5% · Revenue (TTM) 7.5B KRW · Revenue growth (YoY) −14.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).

What moves the price

The share trades about 77% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −14% fair-value upside, at −64%, 065660 screens richer than that median.

Fair Value models

Bear 3,129 KRW Fair Value 4,741 KRW Bull 5,926 KRW
Price 13,140 KRW · Downside -63.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 3,129 KRW 4,741 KRW 5,926 KRW 53
All 1 models by family
Asset-Based
NCAV (Graham) 3,129 KRW 4,741 KRW 5,926 KRW 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 63
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 41/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2020 (pandemic). Over 10 years: +7.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−66.1% (2020) → −32.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

065660 screens overvalued: fair value 64% below the price. Compare with ST Pharm Co →

Compare Anterogen.Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside −63.9% · Bottom 25%
Profitability
Return on assets −1.6% · Bottom 25%
Net margin (12 months) −85.6% · Bottom 25%
Operating margin (12 months) −54.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −14.1% · Bottom 25%
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 1.50× · Pricier than median
P/S (12 months) 17.44× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 13
FUTURE (revenue growth)0 · sector 51
PAST (return on equity)0 · sector 15
HEALTH (low debt)94 · sector 98
DIVIDEND (yield)0 · sector 26

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Kolon Life Science Inc 102940 12,450 KRW 37,195 KRW +199% vs 065660
Huons Global Co 084110 18,880 KRW 47,019 KRW +149% vs 065660
DongKook Pharmaceutical Co 086450 23,350 KRW 28,372 KRW +22% vs 065660
VIKRAMTH VIKRAMTH ₹324.45 ₹351.29 +8% vs 065660
ST Pharm Co 237690 71,500 KRW 61,182 KRW −14% vs 065660
EURO EURO 1.26 PHP 0.8000 PHP −37% vs 065660
Oscotec Inc 039200 36,150 KRW 21,262 KRW −41% vs 065660
BINEX Co 053030 6,140 KRW 1,844 KRW −70% vs 065660
Caregen Co 214370 27,500 KRW 5,414 KRW −80% vs 065660
SHUKRAPHAR SHUKRAPHAR ₹82.11 ₹9.14 −89% vs 065660

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Anterogen.Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Anterogen.Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/065660

Frequently asked questions

Is Anterogen.Co.Ltd (065660) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 4,741 KRW versus a price of 13,140 KRW, about 64% lower (overvalued).
What is the fair value of 065660?
Our model-based fair value for Anterogen.Co.Ltd is 4,741 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 13,140 KRW.
What is the quality score of 065660?
Anterogen.Co.Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anterogen.Co.Ltd (065660)?
Our model-based price target is the fair value of 4,741 KRW (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 3,129 KRW, optimistic scenario 5,926 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Anterogen.Co.Ltd stock forecast for 2026?
Our models put fair value at 4,741 KRW, about 64% lower versus a price of 13,140 KRW (overvalued). Cautious scenario 3,129 KRW, optimistic scenario 5,926 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Anterogen.Co.Ltd (065660)?
Anterogen.Co.Ltd reported trailing-twelve-month revenue of about 7.5B KRW (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Anterogen.Co.Ltd (065660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anterogen.Co.Ltd it is 4,741 KRW per share (as of Nov 4, 2026), against a price of 13,140 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Anterogen.Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 065660 trades above its calculated fair value: price 13,140 KRW, fair value 4,741 KRW, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 065660?
No. The price is what the market pays today (13,140 KRW); the fair value is what the company's own numbers justify (4,741 KRW). For Anterogen.Co.Ltd the two are 8,399 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Anterogen.Co.Ltd worth?
The market values Anterogen.Co.Ltd at about 131B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 13,140 KRW; our models calculate a fair value of 4,741 KRW per share.
What do the bullish and bearish scenarios say about 065660?
Our models span a range for Anterogen.Co.Ltd: cautious scenario 3,129 KRW, base 4,741 KRW, optimistic 5,926 KRW per share (as of Nov 4, 2026, price 13,140 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anterogen.Co.Ltd (065660)?
Balance-sheet figures for Anterogen.Co.Ltd (as of Nov 4, 2026): return on equity −231.8%, debt of 0.12 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 065660 from its 52-week high?
Anterogen.Co.Ltd trades at 13,140 KRW, about 77% below its 52-week high of 58,000 KRW and 4% above the low of 12,600 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 4,741 KRW is for.
Which stocks are comparable to Anterogen.Co.Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anterogen.Co.Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price 13,140 KRW, calculated fair value 4,741 KRW (−64%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 065660 calculated?
We run Anterogen.Co.Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 4,741 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Anterogen.Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anterogen.Co.Ltd (065660)?
The closing price on Nov 9, 2026 was 13,140 KRW. Our model-based fair value is 4,741 KRW, about 64% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anterogen.Co.Ltd right now?
The price sits above even our optimistic bull case (5,926 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3,129 KRW to 5,926 KRW) leaves room in how you read the outcome.

Key figures of Anterogen.Co.Ltd

How large is the market capitalisation of Anterogen.Co.Ltd (065660)?
The market capitalisation of Anterogen.Co.Ltd is 131B KRW (≈ $97.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anterogen.Co.Ltd (065660)?
The price-to-sales ratio of Anterogen.Co.Ltd is 18.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Anterogen.Co.Ltd (065660)?
The net margin of Anterogen.Co.Ltd is −85.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anterogen.Co.Ltd (065660)?
The return on equity (ROE) of Anterogen.Co.Ltd is −232% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anterogen.Co.Ltd (065660)?
On an EBIT basis the return on assets of Anterogen.Co.Ltd is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anterogen.Co.Ltd (065660)?
The operating margin of Anterogen.Co.Ltd is −54.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anterogen.Co.Ltd (065660)?
Revenue at Anterogen.Co.Ltd is growing −14.1% versus a year earlier (3y avg +4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Anterogen.Co.Ltd (065660) generate?
The free cash flow of Anterogen.Co.Ltd is −1.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Anterogen.Co.Ltd (065660) carry?
The net debt of Anterogen.Co.Ltd is 8.4B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Anterogen.Co.Ltd in the live analysis

One click puts Anterogen.Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.